Fig. 5
From: Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity

Role of immune subsets in VEGF–DNP conjugate-mediated tumor inhibition. a DNP immune mice were implanted subcutaneously with 4T1 tumors and treated with VEGF–DNP conjugates as described in Fig. 2. As indicated, mice were treated with depleting anti-CD4, anti-CD8, anti-CD19 and isotype control antibodies, and monitored for tumor growth. CD4 Ab versus isotype control, **p = 0.006; CD19 Ab versus isotype Ab, *p = 0.022, Student’s t-test. (7 mice per group) (n = 2). b Splenocytes from DNP immune (DNP) mice shown in a and from mock immunized mice (KLH) treated with VEGF–DNP were transferred to naive Balb/c mice, challenged with 4T1 tumor subcutaneously and tumor growth was measured. CD8 depletion versus KLH + VEGF–DNP, ***p = 0.0002, Student’s t-test. (7 mice per group) (n = 2). Data are represented as mean ± SEM